The Comparative Research Of Carboplatin And Lobaplatin Adverse Reactions In Digestive System Respectively In Combined Chemotherapy To Treat Gynecological Malignant Tumors

ObjectiveBy comparing the adverse reaction in digestive system with different combined chemotherapies of Paclitaxel/Docetaxel+Carboplatin/Lobaplatin,we aim to offering a reference for choosing different platinum properly and medical surveillance.Method40 cases who were pathologically confirmed the diagnose of Endometrial Cancer,Fallopian Tube Carcinoma and Ovarian Cancer after surgeries from gynecologic department of The First Affiliated Hospital Of GuangXi Medical University from January of 2013 to December of 2015 were enrolled,all these patients received combined chemotherapy containing platinum.The enrollment criteria included:1、Carboplatin+ Paclitaxel/Carboplatin+Docetaxel/ Lobaplatin+ Paclitexel/Lobaplatin+Docetaxel;2、Patients received 4 or above cycles of chemotherapy. All adverse reactions of digestive system and allergic reactions were recorded and analyzed.P<0.05 was considered to indicate statistically significantly different.ResultsIncidence rate of ADR comparison between Paclitaxel and Docetaxel groups.The incidence rate of inappetence,vomiting and abdominal pain were higher in group of Carboplati+Docetaxel when compared with group of Carboplatin+Paclitaxel(P<0.05). No statistically significantly different were shown in comparison of nausea, oral ulcer and diarrhea,there was no blood stool and abnormal liver enzyme changes. No statistically significantly difference was shown in the incidence of ADR in between the groups of Lobaplatin+ Docetaxel and Lobaplatin+ Paclitaxel(P>0.05).Severity of ADR comparison between Placlitaxel and Docetaxel groups.By comparing the severity of ADR in digestive system between the Paclitaxel groups and Docetaxel groups, outcome showed no statistical significant difference (P>0.05).Incidence rate of ADR comparison between Carboplatin and Lobaplatin groups.The incidences of inappetence,nausea,vomiting,oral ulcer and diarrhea in group of Carboplatin+Paclitaxel were much higher than the group of Lobaplatin+ Paclitaxel (P<0.05),the incidence of ADR was lower in group of Lobaplatin+Docetaxel when compared with the group of Carboplatin+ Docetaxel(P<0.05).Severity of ADR comparison between Carboplatin and Lobaplatin groups.Carboplatin groups showed higher incidences and severity (especially the incidence rate of level Ⅲ and level Ⅳ)of ADR in digestive systemic than Lobaplatin groups no matter combined with Placlitaxel or Docetaxel (P<0.05).ConclusionThe incidence rate and severity of ADR in digestive system were lower in Lobaplatin groups than Carboplatin groups when combined with Taxoids as the combined chemotherapy for gynecologic malignant tumors.